Welcome to our dedicated page for Impact Biomedical news (Ticker: IBO), a resource for investors and traders seeking the latest updates and insights on Impact Biomedical stock.
Impact BioMedical Inc. (NYSE American: IBO) is a biotechnology company that focuses on discovering, confirming, and patenting unique science and technologies for human healthcare and wellness. Its news flow reflects this intellectual property–driven model, highlighting developments across platforms such as Linebacker™, Equivir™, Laetose™, and 3F™, as well as corporate transactions and capital markets activity.
News updates often cover patent issuances and IP milestones. For example, the company has announced U.S. and Canadian patents for its Linebacker™ platform targeting inflammatory-related diseases, and U.S. patents within its 3F™ technology platform for insect repelling compositions and functional fragrances aimed at controlling infectious diseases. These announcements describe the scientific focus of each platform and the potential application areas the company is pursuing.
Investors and followers of IBO can also expect corporate and strategic news, including the company’s initial public offering on the NYSE American, shareholder letters outlining strategic vision and platform progress, and updates on acquisitions such as the all-equity purchase of Celios®, an air purification technology company with patented systems designed to deliver high-level indoor air quality.
A significant portion of Impact BioMedical’s recent news relates to merger and transaction activity. The company has disclosed a Merger and Share Exchange Agreement with Dr Ashleys entities and a newly formed PubCo, under which Impact BioMedical and Dr Ashleys are expected to become wholly owned subsidiaries of PubCo, with the combined entity trading on NYSE American under the name “Dr Ashleys Limited,” subject to approvals and closing conditions.
Additional news items include participation in investor conferences, commentary on stock trading activity, and introductions of the executive leadership team. For ongoing coverage of IBO, this news page aggregates company press releases and related announcements so readers can follow patent progress, partnership developments, transaction milestones, and other key corporate events.
Impact BioMedical Inc. (NYSE American: IBO) has successfully closed its initial public offering of 1,500,000 common stock shares at $3.00 per share. Trading began on the NYSE American Market on September 16, 2024, under the ticker symbol 'IBO'. The company granted underwriters a 45-day option to purchase up to 225,000 additional shares. Revere Securities, served as the sole book-running manager and received warrants to purchase up to 75,000 shares (86,250 if over-allotment is fully exercised) at $3.75 per share. The warrants are exercisable from nine months after the offering's commencement until the third anniversary. The SEC declared the registration statement effective on September 13, 2024.
Impact BioMedical Inc. (NYSE American: IBO), a company focused on human healthcare and wellness, has announced the pricing of its initial public offering. The company is offering 1,500,000 shares of common stock at $3.00 per share. Trading is expected to begin on the NYSE American Market on September 16, 2024, under the ticker symbol 'IBO'. The offering is set to close on September 17, 2024, subject to customary conditions. Impact has also granted underwriters a 45-day option to purchase an additional 225,000 shares. Revere Securities, is the book-running manager for the offering. The company has agreed to issue underwriter warrants to purchase up to 75,000 shares (86,250 if over-allotment is exercised), exercisable at 125% of the IPO price.